Pre-plan parameters predict post-implant D90 ≥ 140 Gy for (125)I permanent prostate implants - Abstract

PURPOSE: To find permanent prostate implant (PPI) pre-plan dosimetric parameters that predict post-implant D90 ≥ 140 Gy.

MATERIAL AND METHODS: Pre-plans were evaluated for 504 patients undergoing PPI with 125I seeds for low or intermediate risk prostate cancer. Baseline patient and disease factors, numbers of seeds, ratios of number of seeds to available positions (occupancy proportion), and distances between the 100% isodose line and edge of the prostate (margin) planned for the whole prostate (WP), superior (S), inferior (I), anterior (A), and posterior (P) halves, SA, SP, IA, and IP quarters, and superior (ST), inferior (IT), and middle (MT) thirds, and anterior (AT) and posterior (PT) middle one-sixth segments were analyzed by post-implant D90 subset (≥ 140 Gy vs. < 140 Gy).

RESULTS: 20% had post-implant D90 < 140 Gy (mean: 128.0 Gy, range: 97.5-139.2) vs. ≥ 140 Gy (mean: 154.4 Gy, range: 140.0-193.5). The D90 ≥ 140 Gy subset had larger AT and IA segment mean numbers of seeds (p = 0.01, 0.046), larger WP, S, A, SA, ST, AT, and MT segment mean margins (p = 0.01, 0.01, 0.001, 0.0001, 0.03, 0.005, 0.02), and lower PT segment occupancy proportion (p = 0.004). On multivariate analysis, independent predictors of post-implant D90 ≥ 140 Gy were increased SA mean margin, no pre-implant 5-α-reductase inhibitor, higher pre-plan D90, decreased P occupancy proportion, no pre-implant hormone therapy, and decreased SP mean margin.

CONCLUSIONS: Higher occupancy proportion and larger margins anteriorly and reduced occupancy proportion, and smaller margins posteriorly on PPI pre-plans predict post-implant D90 ≥ 140 Gy.

Written by:
Alexander J, Weinberg V, Gottschalk AR, Hsu IC, Shinohara K, Roach M 3rd.   Are you the author?
Department of Radiation Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA; Biostatistics Core, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA; Department of Urology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California, USA.

Reference: J Contemp Brachytherapy. 2014 Jun;6(2):143-53.
doi: 10.5114/jcb.2014.43248


PubMed Abstract
PMID: 25097554

UroToday.com Prostate Cancer Section

 

 

 

 

 

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe